Novo Nordisk’s Oral Wegovy Wins EU Nod: Can the Pill’s US Success Scale Across 27 Markets?

EU approves Novo Nordisk's daily oral semaglutide pill for obesity, offering a needle-free alternative and driving $355M in Q1 sales despite stock dip.

For millions of Europeans who have shunned weight-loss injections, the arrival of a daily pill could change the calculus. Novo Nordisk has secured EU approval for an oral version of Wegovy, giving patients a needle-free alternative and the company a fresh weapon in an increasingly crowded obesity market. The European Commission greenlit the 25-milligram semaglutide tablet on 15 July 2026, alongside a higher-dose 7.2-milligram injectable formulation, making them available across all 27 EU member states plus Norway, Iceland and Liechtenstein.

The approval follows a positive review by the European Medicines Agency in May and is backed by the OASIS clinical programme, which showed a roughly 17% weight loss over 68 weeks for the oral 25-mg dose. A third of participants shed 20% or more. Novo Nordisk plans to roll out the pill in additional countries during the second half of 2026, building on early momentum elsewhere.

That momentum is already tangible. In the United States — where the tablet launched in January 2026 — along with the UK and the United Arab Emirates, the product generated $355 million in first?quarter sales and captured a 60% share of new obesity?drug prescriptions within just 22 weeks. CEO Mike Doustdar framed the EU approval as a direct response to patient reluctance around injections, noting that the pill form could significantly boost adherence.

Production Ramp?Up Gathers Pace

Meeting demand across 27 countries simultaneously requires a manufacturing overhaul, and Novo Nordisk is investing heavily to avoid past supply constraints. In Bohumil, Czech Republic, the company has started producing carrier proteins — a precursor for next?generation diabetes and obesity drugs — after a roughly $360 million investment. In Tianjin, China, an additional $29 million is being deployed to modernise injection?pen assembly lines. The most ambitious expansion is in Athlone, Ireland, where a €432 million facility is being retooled to become the company’s central hub for oral GLP?1 production outside the US.

The group now operates seven production sites worldwide, a step?change from the capacity bottlenecks that plagued it two years ago.

Stock Shows Recovery but Remains in the Shadow of the 52?Week High

The approval news did little to lift the shares on the day, with Novo Nordisk closing at €43.95, down 2.42%. Yet the broader trend tells a different story: over the past 30 days the stock has rallied nearly 16%, and it trades roughly 10% above its 50?day moving average of €40.03. The relative strength index of 62.6 points to upward momentum without suggesting overbought conditions.

Still, the share price is 27.89% below its 52?week high of €60.95, reflecting a market that welcomes the regulatory win but remains cautious about execution. Management has labelled 2026 a “trough and reset year” for the revenue base. Consensus estimates for the current quarter point to a 2.9% year?on?year sales decline and a 15.5% drop in earnings per share.

In a sign that the board sees value, Novo Nordisk has continued its share?buyback programme. Since February, the company has repurchased approximately 24 million B?shares, part of a total programme worth 15 billion Danish kroner. The purchases, which ran through 10 July, signal management’s belief that the stock is undervalued after a year of weakness.

The Competitive Challenge Looms Larger

The oral Wegovy gives Novo Nordisk a first?mover advantage in the EU’s oral GLP?1 segment, but the window of exclusivity may be narrow. Eli Lilly is pushing ahead with its own oral candidate, Orforglipron, which is already under EU review and could reach the market in 2027. Lilly has also filed for approval of Orforglipron in China, adding pressure on Novo Nordisk’s international expansion.

Boehringer Ingelheim is developing multi?agonists for obesity, and the broader GLP?1 landscape is fragmenting fast. Novo Nordisk’s own pipeline includes candidates such as Zenagamtide and UBT251 for obesity and related conditions, and positive phase?3 data for Denecimig in haemophilia A underline that the company is not a one?trick GLP?1 pony. But not every candidate delivers — Cagrisema recently disappointed in trials, and the growing reliance on self?pay prescriptions for international launches introduces more volatile revenue streams than traditional reimbursement models.

The Real Test: Reimbursement and Rollout

The biggest hurdle for the Wegovy pill in Europe lies not in the approval itself but in how quickly each country’s health authorities agree to list and reimburse it. National processes vary widely in speed and scope, and Novo Nordisk must negotiate these individually. Any meaningful delay in the largest markets — Germany, France, Italy, Spain — would blunt the European opportunity.

The market’s muted reaction on approval day suggests investors are pricing in exactly this uncertainty. The next concrete checkpoint will be the first EU sales figures for the oral Wegovy in the second half of 2026. If they mirror the US trajectory, the stock could regain lost ground. If reimbursement drags or Lilly accelerates its own oral launch, the current rally may prove short?lived. For now, Novo Nordisk has the regulatory ticket — it just needs to turn it into a commercial passport.